Aileron Therapeutics, Inc., a Cambridge, Massachusetts-based biopharmaceutical company developing and advancing an innovative class of drugs called Stapled Peptides, raised $12m as a second tranche of its Series D financing.
Backers included current investors Apple Tree Partners, Excel Venture Management, Lilly Ventures, Novartis Venture Funds, Roche Venture Fund and SR One.
Led by Joseph A. Yanchik III, president and chief executive officer, Aileron Therapeutics has been advancing proprietary Stapled Peptide drugs, which aim to attack the key drivers of complex diseases such as cancer, metabolic and endocrine conditions and inflammation.
The company intends to use this funding, which brings the total amount of the round to $42m, to develop their ALRN-5281 in patients with orphan endocrine disorders early this year and to continue to advance their pipeline of Stapled Peptide drugs in collaboration with Roche, including a specific dual inhibitor of MDM2 and MDMX for p53-dependent cancers.
ALRN-5281 is a proprietary, long-acting growth-hormone-releasing hormone (GHRH) agonist for treating orphan endocrine disorders, including adult growth hormone (GH) deficiency and HIV lipodystrophy, as well as broader patient populations involving a wide variety of metabolic and endocrine disorders. Aileron is also advancing Stapled Peptide drug candidates.